ERBB2 and breast carcinoma: Triple negative breast cancer (TNBC) represents approximately 15–20% of patients with breast carcinomas and is characterized by the lack of expression of estrogen and progesterone receptors (ER/PR) and neither expression nor amplification of the HER2 oncogene [2].